ATE439861T1 - Verfahren zur modulierung von cd200-rezeptoren - Google Patents

Verfahren zur modulierung von cd200-rezeptoren

Info

Publication number: ATE439861T1
Authority: AT; Austria
Prior art keywords: modulating; receptors; methods; agonists; antagonists
Prior art date: 2002-03-15

Application number

AT03716515T

Other languages

English (en)

Inventor

Holly Cherwinski

Joseph Phillips

Jonathon Sedgwick

Michael Bigler

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-03-15

Filing date

2003-03-13

Publication date

2009-09-15

2003-03-13 Application filed by Schering Corp filed Critical Schering Corp

2009-09-15 Application granted granted Critical

2009-09-15 Publication of ATE439861T1 publication Critical patent/ATE439861T1/de

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Oncology (AREA)
Heart & Thoracic Surgery (AREA)
Communicable Diseases (AREA)
Genetics & Genomics (AREA)
Hospice & Palliative Care (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Dermatology (AREA)
Gastroenterology & Hepatology (AREA)
Virology (AREA)
Psychology (AREA)
Otolaryngology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Psychiatry (AREA)

AT03716515T 2002-03-15 2003-03-13 Verfahren zur modulierung von cd200-rezeptoren ATE439861T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US36451302P	2002-03-15	2002-03-15
PCT/US2003/007647 WO2003077947A1 (en)	2002-03-15	2003-03-13	Methods of modulating cd200 receptors

Publications (1)

Publication Number	Publication Date
ATE439861T1 true ATE439861T1 (de)	2009-09-15

Family

ID=28041929

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03716515T ATE439861T1 (de)	2002-03-15	2003-03-13	Verfahren zur modulierung von cd200-rezeptoren

Country Status (16)

Country	Link
US (3)	US20030223991A1 (de)
EP (3)	EP2100617A1 (de)
JP (4)	JP2005529587A (de)
AT (1)	ATE439861T1 (de)
AU (3)	AU2003220219A1 (de)
CA (1)	CA2478803A1 (de)
CY (1)	CY1109521T1 (de)
DE (1)	DE60328870D1 (de)
DK (1)	DK1482973T3 (de)
ES (1)	ES2330211T3 (de)
MX (1)	MXPA04008937A (de)
NZ (2)	NZ570998A (de)
PT (1)	PT1482973E (de)
SI (1)	SI1482973T1 (de)
WO (1)	WO2003077947A1 (de)
ZA (2)	ZA200407384B (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2000070045A1 (en) *	1999-05-13	2000-11-23	Medical Research Council	Ox2 receptor homologs
EP2316485A1 (de)	2001-10-12	2011-05-04	Schering Corporation	Verwendung von bispezifischen Antikörpern zur Regulierung der Immunreaktion
EP2100617A1 (de) *	2002-03-15	2009-09-16	Schering Corporation	Verfahren zur Modellierung von CD200-Rezeptoren
JP4763282B2 (ja) *	2002-06-07	2011-08-31	トリリウムセラピューティクスインコーポレーティッド	骨発生の調節方法
US20040213783A1 (en) *	2002-12-27	2004-10-28	Janet Liversidge	Methods of inducing and maintaining immune tolerance
EP1718333A2 (de) *	2004-02-02	2006-11-08	Schering Corporation	Verfahren zur modulation von cd200 und cd200r
JP4919453B2 (ja) *	2005-04-07	2012-04-18	独立行政法人理化学研究所	炎症性疾患の予防又は治療剤
US9254293B2 (en)	2006-06-16	2016-02-09	The Trustees Of The University Of Pennsylvania	Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and BPH
SG191442A1 (en) *	2006-12-22	2013-07-31	Schering Corp Us	Antibodies to cd200r
CA2674578A1 (en) *	2007-01-11	2008-07-24	Boehringer Ingelheim International Gmbh	Cd200 and its receptor, cd200r, modulate bone mass via the differentiation of osteoclasts
WO2009004339A2 (en) *	2007-07-03	2009-01-08	Imperial Innovations Limited	Compositions and methods relating to manipulation of the myeloid immune compartment during respiratory infection
EP2432805A1 (de) *	2009-05-20	2012-03-28	Schering Corporation	Modulation von pilr-rezeptoren zur behandlung von sepsis
US20120128673A1 (en)	2009-05-20	2012-05-24	Schering Corporation	Modulation of pilr receptors to treat microbial infections
WO2011084357A1 (en)	2009-12-17	2011-07-14	Schering Corporation	Modulation of pilr to treat immune disorders
US20150231215A1 (en)	2012-06-22	2015-08-20	Randolph J. Noelle	VISTA Antagonist and Methods of Use
US10745467B2 (en)	2010-03-26	2020-08-18	The Trustees Of Dartmouth College	VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
NZ602634A (en)	2010-03-26	2015-06-26	Dartmouth College	Vista regulatory t cell mediator protein, vista binding agents and use thereof
US9890215B2 (en)	2012-06-22	2018-02-13	King's College London	Vista modulators for diagnosis and treatment of cancer
JP6285923B2 (ja) *	2012-06-22	2018-02-28	トラスティーズ・オブ・ダートマス・カレッジ	新規ＶＩＳＴＡ−Ｉｇコンストラクト及び自己免疫、アレルギー性及び炎症性障害の処置のためのＶＩＳＴＡ−Ｉｇの使用
CN109793893B (zh)	2012-09-07	2023-05-26	达特茅斯大学理事会	用于诊断和治疗癌症的vista调节剂
JP5854432B2 (ja) *	2012-09-28	2016-02-09	森永乳業株式会社	アレルギー反応検出法
US11014987B2 (en)	2013-12-24	2021-05-25	Janssen Pharmaceutics Nv	Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
LT3712174T (lt)	2013-12-24	2022-05-25	Janssen Pharmaceutica Nv	Anti vista antikūnai ir fragmentai
AU2015274504B2 (en)	2014-06-11	2021-02-04	Kathy A. Green	Use of VISTA agonists and antagonists to suppress or enhance humoral immunity
AU2015357463B2 (en)	2014-12-05	2021-10-07	Immunext, Inc.	Identification of VSIG8 as the putative vista receptor and its use thereof to produce vista/VSIG8 modulators
EP3722314A1 (de)	2015-06-24	2020-10-14	Janssen Pharmaceutica NV	Anti-vista-antikörper und -fragmente
US10899836B2 (en)	2016-02-12	2021-01-26	Janssen Pharmaceutica Nv	Method of identifying anti-VISTA antibodies
US20210017281A1 (en)	2016-04-15	2021-01-21	Immunext, Inc.	Anti-human vista antibodies and use thereof
TWI749367B (zh) *	2018-09-14	2021-12-11	美商美國禮來大藥廠	Cd200r促效劑抗體及其用途

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US5202267A (en)	1988-04-04	1993-04-13	Hygeia Sciences, Inc.	Sol capture immunoassay kit and procedure
US5468468A (en)	1989-02-09	1995-11-21	The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services	Method for making a monoclonal antibody, monoclonal antibodies to α PD
US6176962B1 (en)	1990-02-28	2001-01-23	Aclara Biosciences, Inc.	Methods for fabricating enclosed microchannel structures
EP0469477B1 (de) *	1990-08-02	1995-09-20	F. Hoffmann-La Roche Ag	Antiallergische Mischung
US5440021A (en)	1991-03-29	1995-08-08	Chuntharapai; Anan	Antibodies to human IL-8 type B receptor
US5783415A (en)	1991-03-29	1998-07-21	Genentech, Inc.	Method of producing an IL-8 receptor polypeptide
US5932448A (en)	1991-11-29	1999-08-03	Protein Design Labs., Inc.	Bispecific antibody heterodimers
US6129914A (en)	1992-03-27	2000-10-10	Protein Design Labs, Inc.	Bispecific antibody effective to treat B-cell lymphoma and cell line
US5532210A (en)	1994-06-08	1996-07-02	E. I. Du Pont De Nemours And Company	High temperature superconductor dielectric slow wave structures for accelerators and traveling wave tubes
US6132764A (en)	1994-08-05	2000-10-17	Targesome, Inc.	Targeted polymerized liposome diagnostic and treatment agents
US5919816A (en)	1994-11-14	1999-07-06	Bionumerik Pharmaceuticals, Inc.	Formulations and methods of reducing toxicity of antineoplastic agents
US5888530A (en)	1995-07-21	1999-03-30	The General Hospital Corporation	Method of enhancing delivery of a pharmaceutical formulation
US6096728A (en)	1996-02-09	2000-08-01	Amgen Inc.	Composition and method for treating inflammatory diseases
EP0908466B1 (de)	1996-05-27	2006-04-26	Medical & Biological Laboratories Co., Ltd.	Antikörper gegen menschliches lect2, zellen die diesen produzieren und verfahren und kit zu dessen bestimmung
US6056973A (en)	1996-10-11	2000-05-02	Sequus Pharmaceuticals, Inc.	Therapeutic liposome composition and method of preparation
JPH10212242A (ja) *	1996-11-27	1998-08-11	Tosoh Corp	新規血小板増多剤
US6294170B1 (en)	1997-08-08	2001-09-25	Amgen Inc.	Composition and method for treating inflammatory diseases
US5948627A (en)	1997-05-30	1999-09-07	One Lambda	Immunobead flow cytometric detection of anti-HLA panel-reactive antibody
US6342220B1 (en)	1997-08-25	2002-01-29	Genentech, Inc.	Agonist antibodies
US6989435B2 (en) *	1997-09-11	2006-01-24	Cambridge University Technical Services Ltd.	Compounds and methods to inhibit or augment an inflammatory response
US5842787A (en)	1997-10-09	1998-12-01	Caliper Technologies Corporation	Microfluidic systems incorporating varied channel dimensions
JPH11246435A (ja) *	1997-10-29	1999-09-14	Ajinomoto Co Inc	免疫調整剤
US6312689B1 (en)	1998-07-23	2001-11-06	Millennium Pharmaceuticals, Inc.	Anti-CCR2 antibodies and methods of use therefor
JP2002521055A (ja) *	1998-07-30	2002-07-16	ヒューマンジノームサイエンシーズ，インコーポレイテッド	９８個のヒト分泌タンパク質
CA2352572C (en)	1998-12-01	2010-04-20	Protein Design Labs, Inc.	Humanized antibodies to gamma-interferon
WO2000070045A1 (en) *	1999-05-13	2000-11-23	Medical Research Council	Ox2 receptor homologs
WO2002011762A2 (en) *	2000-08-03	2002-02-14	Gorczynski Reginald M	Methods and compositions for modulating tumor growth
WO2002088164A1 (en)	2001-04-26	2002-11-07	Immunex Corporation	Human ox2 receptors
WO2002095030A2 (en) *	2001-05-24	2002-11-28	Trillium Therapeutics Inc.	Modulation of cd200 receptors
EP2316485A1 (de) *	2001-10-12	2011-05-04	Schering Corporation	Verwendung von bispezifischen Antikörpern zur Regulierung der Immunreaktion
US20040126777A1 (en) *	2002-01-28	2004-07-01	Bhatt Ramesh Rajani	Lp mammalian proteins; related reagents
EP2100617A1 (de) *	2002-03-15	2009-09-16	Schering Corporation	Verfahren zur Modellierung von CD200-Rezeptoren

2003
- 2003-03-13 EP EP09163830A patent/EP2100617A1/de not_active Withdrawn
- 2003-03-13 JP JP2003576000A patent/JP2005529587A/ja active Pending
- 2003-03-13 EP EP10183878A patent/EP2322218A1/de not_active Withdrawn
- 2003-03-13 CA CA002478803A patent/CA2478803A1/en not_active Abandoned
- 2003-03-13 PT PT03716515T patent/PT1482973E/pt unknown
- 2003-03-13 DK DK03716515T patent/DK1482973T3/da active
- 2003-03-13 US US10/389,231 patent/US20030223991A1/en not_active Abandoned
- 2003-03-13 DE DE60328870T patent/DE60328870D1/de not_active Expired - Lifetime
- 2003-03-13 NZ NZ570998A patent/NZ570998A/en not_active IP Right Cessation
- 2003-03-13 WO PCT/US2003/007647 patent/WO2003077947A1/en active Application Filing
- 2003-03-13 MX MXPA04008937A patent/MXPA04008937A/es active IP Right Grant
- 2003-03-13 AU AU2003220219A patent/AU2003220219A1/en not_active Abandoned
- 2003-03-13 AT AT03716515T patent/ATE439861T1/de active
- 2003-03-13 ES ES03716515T patent/ES2330211T3/es not_active Expired - Lifetime
- 2003-03-13 NZ NZ553470A patent/NZ553470A/en not_active IP Right Cessation
- 2003-03-13 SI SI200331692T patent/SI1482973T1/sl unknown
- 2003-03-13 EP EP03716515A patent/EP1482973B1/de not_active Expired - Lifetime
2004
- 2004-09-14 ZA ZA200407384A patent/ZA200407384B/xx unknown
2006
- 2006-03-03 JP JP2006058745A patent/JP2006206598A/ja active Pending
- 2006-06-29 US US11/478,778 patent/US20060240010A1/en not_active Abandoned
2007
- 2007-06-26 AU AU2007202938A patent/AU2007202938B2/en not_active Ceased
2008
- 2008-03-10 US US12/045,153 patent/US8263070B2/en not_active Expired - Fee Related
2009
- 2009-10-26 CY CY20091101112T patent/CY1109521T1/el unknown
2010
- 2010-03-04 ZA ZA2010/01595A patent/ZA201001595B/en unknown
2011
- 2011-04-20 AU AU2011201824A patent/AU2011201824A1/en not_active Abandoned
- 2011-06-16 JP JP2011134635A patent/JP2011178813A/ja not_active Withdrawn
- 2011-06-16 JP JP2011134634A patent/JP2011178812A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
WO2003077947A1 (en)	2003-09-25
CA2478803A1 (en)	2003-09-25
JP2006206598A (ja)	2006-08-10
US20060240010A1 (en)	2006-10-26
JP2011178812A (ja)	2011-09-15
NZ570998A (en)	2010-08-27
AU2007202938B2 (en)	2011-01-20
DK1482973T3 (da)	2009-12-07
EP1482973A1 (de)	2004-12-08
ZA200407384B (en)	2010-05-26
CY1109521T1 (el)	2014-08-13
AU2003220219A1 (en)	2003-09-29
US20080166353A1 (en)	2008-07-10
MXPA04008937A (es)	2005-06-17
ZA201001595B (en)	2012-11-28
EP1482973B1 (de)	2009-08-19
ES2330211T3 (es)	2009-12-07
SI1482973T1 (sl)	2010-01-29
JP2005529587A (ja)	2005-10-06
US8263070B2 (en)	2012-09-11
EP2322218A1 (de)	2011-05-18
NZ553470A (en)	2008-10-31
US20030223991A1 (en)	2003-12-04
JP2011178813A (ja)	2011-09-15
AU2007202938A1 (en)	2007-07-19
EP2100617A1 (de)	2009-09-16
DE60328870D1 (de)	2009-10-01
PT1482973E (pt)	2009-11-20
AU2011201824A1 (en)	2011-05-19
EP1482973A4 (de)	2006-03-08

Publication	Publication Date	Title
ATE439861T1 (de)	2009-09-15	Verfahren zur modulierung von cd200-rezeptoren
DE60025368D1 (de)	2006-03-30	Verfahren zum identifizieren von prostaglandin d2 rezeptor modulatoren
ES2137320T3 (es)	1999-12-16	Derivados de decahidro-isoquinoleina.
DE60027405D1 (de)	2006-05-24	Verfahren zur steigerung der aktivität von haustieren
BRPI0507808A (pt)	2007-07-10	métodos de modular a atividade de citocina; reagentes relacionados
DE69623513D1 (de)	2002-10-17	Verfahren zur Charakterisierung von Kohlenwasserstoffen mittels Infrarotspektroskopie
DE69719263D1 (de)	2003-04-03	Arbeitseinheit, elektrophotographisches Bilderzeugungsgerät und Verfahren zum Übertragen von Antriebskraft zur Arbeitseinheit
DE60326527D1 (de)	2009-04-23	Verfahren und Gerät zur Ultraschallkontrastbildformung unter Benutzung von gestuften Chirp-Wellenformen
NO944578L (no)	1995-06-06	Eksitatoriske aminosyre reseptor antagonister
DE60239522D1 (de)	2011-05-05	Verfahren zur behandlung von autoimmunerkrankungen bei einem probanden und diagnostische in-vitro-assays
DE60335216D1 (de)	2011-01-13	Adiponektin-rezeptor und dafür kodierendes gen
ATE354364T1 (de)	2007-03-15	Verwendung von at-1 rezeptorantagonisten oder at- 2 rezeptormodulatoren zur behandlung von erkrankungen, die mit einer erhöhung an at-1 oder at-2 rezeptoren verbunden sind
BRPI0507776A (pt)	2007-07-10	métodos de modular a atividade de citocina; reagentes relacionados
DE60020571D1 (de)	2005-07-07	Verfahren und vorrichtung zur unterscheidung und zählung von leukozyten
EA199900912A1 (ru)	2000-04-24	Фармацевтические средства
DE60209296D1 (de)	2006-04-27	Verfahren und Apparat zur Reinigung der Halshaut von Schlachtgeflügel
DE69524623D1 (de)	2002-01-24	Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
ES2055036T3 (es)	1994-08-16	Antagonistas tetrazolicos de receptores de aminoacidos excitadores.
ATE432350T1 (de)	2009-06-15	G-protein gekoppelte rezeptoren
DE60033576D1 (de)	2007-04-05	Methoden zum screening knochenmorphogenetishemimetika
EP1368723A4 (de)	2009-09-09	Integriertes system und verfahren zum zentralisierten behandeln von transitinformationen
DE50001711D1 (de)	2003-05-15	Vorrichtung und verfahren zur verklebung von fügeteilen
DE3851183D1 (de)	1994-09-29	Verfahren und Gerät zur Diagnostik von Augenleiden.
DE69801786D1 (de)	2001-10-31	Verfahren, Vorrichtung und Produkt zur Verlängerung von menschlichem Haar
ATE545866T1 (de)	2012-03-15	Liganden von g-protein-gekoppelten rezeptoren und verfahren

Legal Events

Date	Code	Title	Description
2010-03-15	UEP	Publication of translation of european patent specification	Ref document number: 1482973 Country of ref document: EP

Date

Code

Title

Description

2010-03-15

UEP

Publication of translation of european patent specification

Ref document number: 1482973

Country of ref document: EP